Details of the Drug

General Information of Drug (ID: DMNZWL7)

Drug Name
Moclobemide
Synonyms
Arima; Aurorex; Aurorix; Deprenorm; Feraken; Manerix; Moclaime; Moclamide; Moclamine; Moclix; Moclobamide; Moclobemid; Moclobemida; Moclobemidum; Moclobeta; Moclodura; Moclonorm; NovoMoclobemide; NuMoclobemide; Rimoc; Alphapharm Brand of Moclobemide; Alpharma Brand of Moclobemide; Apo Moclobemide; Apotex Brand of Moclobemide; Azupharma Brand of Moclobemide; BC Brand of Moclobemide; Betapharm Brand of Moclobemide; Bull Brand of Moclobemide; Chem mart Brand of Moclobemide; Chem mart Moclobemide; Ct Arzneimittel Brand of Moclobemide; DBL Moclobemide; Esparma Brand of Moclobemide; Faulding Brand of Moclobemide; GenRX Moclobemide; Healthsense Brand of Moclobemide; Healthsense Moclobemide; Hexal Brand of Moclobemide; Hoffmann La Roche Brand of Moclobemide; Kendrick Brand of Moclobemide; Merck dura Brand of Moclobemide; Moclobemid AZU; Moclobemid Puren; Moclobemid Stada; Moclobemid ratiopharm; Moclobemid von ct; Moclobemide Alphapharm Brand; Moclobemide Alpharma Brand; Moclobemide Apotex Brand; Moclobemide Azupharma Brand; Moclobemide BC Brand; Moclobemide Bull Brand; Moclobemide Faulding Brand; Moclobemide Healthsense Brand; Moclobemide Hexal Brand; Moclobemide Kendrick Brand; Moclobemide Novopharm Brand; Moclobemide Pharmascience Brand; Moclobemide Roche Brand; Moclobemide Stadapharm Brand; Moclobemide Temmler Brand; Moclobemide betapharm Brand; Moclobemide esparma Brand; Moclobemide ratiopharm Brand; Novo Moclobemide; Novopharm Brand of Moclobemide; Nu Moclobemide; Nu Pharm Brand of Moclobemide; PMS Moclobemide; Pharmascience Brand of Moclobemide; Ratiopharm Brand of Moclobemide; Roche Brand of Moclobemide; Stadapharm Brand of Moclobemide; Temmler Brand of Moclobemide; Terry White Chemists Brand of Moclobemide; Terry White Chemists Moclobemide; CBMicro_048319; Moclobemid 1A Pharma; Moclobemid1A Pharma; Moclobemide 1A Brand; Ro 11 1163; AZU, Moclobemid; Apo-Moclobemide; Aurorix (TN); Ct-Arzneimittel Brand of Moclobemide; Hoffmann-La Roche Brand of Moclobemide; Manerix (TN); Moclobemid-1A Pharma; Moclobemid-Puren; Moclobemid-ratiopharm; Moclobemida [INN-Spanish]; Moclobemide Nu-Pharm Brand; Moclobemide ct-Arzneimittel Brand; Moclobemide, Chem mart; Moclobemide, DBL; Moclobemide, GenRX; Moclobemide, Healthsense; Moclobemidum [INN-Latin]; Novo-Moclobemide; Nu-Moclobemide; Nu-Pharm Brand of Moclobemide; PMS-Moclobemide; Ro 11-1163; Stada, Moclobemid; Von ct, Moclobemid; GNF-PF-695; Moclobemide (USAN/INN); Moclobemide [USAN:BAN:INN]; Moclobemide [USAN:INN:BAN]; Ro 11-1163/000; Ro-11-1163; P-Chloro-N-(2-morpholinoethyl)benzamide; 1A Brand of Moclobemide; 4-Chlor-N-(2-morpholinoethyl)benzamid; 4-Chloro-N-(2-(4-morpholinyl)ethyl)benzamide; 4-Chloro-N-(2-morpholin-4-yl-ethyl)-benzamide; 4-chloro-N-(2-morpholin-4-ylethyl)benzamide; 4-chloro-N-[2-(morpholin-4-yl)ethyl]benzamide
Indication
Disease Entry ICD 11 Status REF
Depression 6A70-6A7Z Approved [1]
Skin imperfections EK71 Patented [2]
Therapeutic Class
Antidepressants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 268.74
Logarithm of the Partition Coefficient (xlogp) 1.5
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 2-6 h [3]
Bioavailability
The bioavailability of drug is 70% [3]
Clearance
The clearance of drug is 30-78 L/h [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 1 - 2 hours [5]
Metabolism
The drug is metabolized via the liver [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.77% [5]
Vd
The volume of distribution (Vd) of drug is 1-1.5 L/kg [4]
Chemical Identifiers
Formula
C13H17ClN2O2
IUPAC Name
4-chloro-N-(2-morpholin-4-ylethyl)benzamide
Canonical SMILES
C1COCCN1CCNC(=O)C2=CC=C(C=C2)Cl
InChI
InChI=1S/C13H17ClN2O2/c14-12-3-1-11(2-4-12)13(17)15-5-6-16-7-9-18-10-8-16/h1-4H,5-10H2,(H,15,17)
InChIKey
YHXISWVBGDMDLQ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4235
ChEBI ID
CHEBI:83531
CAS Number
71320-77-9
DrugBank ID
DB01171
TTD ID
D01ZSO
VARIDT ID
DR00838
INTEDE ID
DR1103
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Monoamine oxidase (MAO) TT32XQJ NOUNIPROTAC Inhibitor [2]
Monoamine oxidase type A (MAO-A) TT3WG5C AOFA_HUMAN Inhibitor [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [8]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [9]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [10]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Amine oxidase A (MAOA) OT8NIWMQ AOFA_HUMAN Gene/Protein Processing [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Depression
ICD Disease Classification 6A70-6A7Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Monoamine oxidase type A (MAO-A) DTT MAOA 8.14E-01 0.05 0.1
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 2.40E-01 -3.31E-02 -1.97E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 7.30E-01 -1.91E-02 -1.41E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 1.90E-01 -9.81E-03 -5.96E-02
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7428).
2 Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
3 Odanacatib, a selective cathepsin K inhibitor, demonstrates comparable pharmacodynamics and pharmacokinetics in older men and postmenopausal women. J Clin Endocrinol Metab. 2014 Feb;99(2):552-60. doi: 10.1210/jc.2013-1688. Epub 2013 Nov 25.
4 Monamine Oxidase Inhibitors
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Zagelbaum NK, Yandrapalli S, Nabors C, Frishman WH: Bempedoic Acid (ETC-1002): ATP Citrate Lyase Inhibitor: Review of a First-in-Class Medication with Potential Benefit in Statin-Refractory Cases. Cardiol Rev. 2019 Jan/Feb;27(1):49-56. doi: 10.1097/CRD.0000000000000218.
7 Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum Psychopharmacol. 2002 Dec;17(8):401-5.
8 Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther. 1995 Jun;57(6):670-7.
9 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
10 Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther. 2001 Apr;69(4):266-73.
11 Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors. J Med Chem. 2011 Oct 27;54(20):7127-37.